U.S. Markets closed

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
318.46+3.43 (+1.09%)
At close: 4:00PM EDT
People also watch
Full screen
Previous Close315.03
Bid317.40 x 100
Ask400.00 x 100
Day's Range311.30 - 319.34
52 Week Range244.28 - 330.00
Avg. Volume1,276,100
Market Cap67.33B
PE Ratio (TTM)20.90
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Investopedia2 days ago

    Gilead, Amgen, and Biogen May Lift Biotech Higher

    These drug juggernauts could bolster the entire biotechnology sector as we head toward year-end.

  • Yahoo Finance2 days ago

    Today's charts: Tesla, AMD developing new AI chip; Blue Apron shares gain; Biogen downgrade; Amazon expands in New York

    Tesla (TSLA) is teaming up with AMD (AMD) to develop its own AI chip for self-driving cars, according to a report by CNBC. Jefferies analyst Mark Lipacis wrote it’s a “critical win” for AMD. On the other hand, Nvidia (NVDA) shares are falling on the news, since a partnership with AMD would make Tesla less reliant on the company.

  • Barrons.com2 days ago

    Biogen: Buy or Hold?

    Just as one analyst goes bullish on Biogen (BIIB), another has moved to the sidelines. Earlier today, Raymond James analyst Laura Chico cut her rating on the stock by two notches, from a Strong Buy to a Market Perform (skipping over Outperform entirely) and lowered her price target from $329 a share to $319 a share. Chico sees continued headwinds for Biogen’s all-important multiple sclerosis drug franchise as a rival drug from Roche (RHHBY) gains market share.